Longevity & AgingResearch PaperOpen Access

Stroke Burden Keeps Rising Worldwide, and Most Risk Is Modifiable

A broad review maps global stroke epidemiology, risk factors, and treatment limits, and points to stem cell therapy as a hopeful regenerative option.

Monday, November 16, 2026 3 views
Published in MedComm (2020)
Glowing 3D brain cross-section with a blocked artery, a clot, and a salvageable penumbra zone shown in warm light

Summary

This review covers stroke epidemiology, risk factors, pathophysiology, and clinical management, with a focus on ischemic stroke (about 87% of cases). Stroke is the second leading cause of death worldwide, with 11.9 million new cases and 7.3 million deaths each year. Low- and middle-SDI regions carry 86% of deaths. Risk differs by age, sex, and race. Hypertension is the leading modifiable risk factor, and diabetes also adds substantial risk. Together, modifiable factors account for over 90% of stroke risk. Reperfusion therapies (tPA within 4.5 hours, thrombectomy within 6 hours) reach few patients, so the authors highlight regenerative approaches, especially stem cell therapy, as a promising direction. The supplied text ends partway through the risk factor section.

0:00--:--

Detailed Summary

Stroke is a leading cause of death and disability worldwide, and its burden is still growing as populations age. This review pulls together epidemiology, risk factors, injury mechanisms, signaling pathways, and clinical management. It gives particular attention to ischemic stroke (IS) and to regenerative therapies, especially stem cells.

The review is narrative and draws on published cohort studies, meta-analyses, Mendelian randomization work, and global burden data. It is not a systematic review or a new study. Stroke is divided into IS (about 87% of cases), hemorrhagic stroke (about 10%), and subarachnoid hemorrhage (about 3%). Transient ischemic attack (TIA) is treated as an early warning sign. In IS, the ischemic core is irreversibly damaged, while the surrounding penumbra can be saved if blood flow returns in time. Injury involves energy failure, ion imbalance, oxidative stress, neuroinflammation, programmed cell death, blood–brain barrier disruption, and edema.

Globally, stroke is the second leading cause of death (10.7% of deaths) and the fourth leading cause of DALYs. About 93.8 million people live with its consequences, with 11.9 million new cases and 7.3 million deaths yearly. Over 30 years, new strokes rose 70% and prevalence rose 85%, even though age-standardized incidence fell. Low- and middle-SDI regions account for 86% of deaths and 89% of DALYs. Sub-Saharan Africa has two to three times the incidence of Western Europe and the US, and few stroke units. Rural areas show higher mortality, for example 19% higher in the rural US South. Incidence also differs by age and sex: young women have more strokes than young men, middle-aged men more than women, and women over 65 more than men. Strokes in young adults are rising, by up to 40% globally. Black individuals have higher incidence (IRR 1.51, and 4.02 at ages 45–54). After a TIA, cumulative stroke risk is 1.2% at 2 days, 5.0% at 30 days, and 7.4% at 90 days.

Modifiable factors, including hypertension, diabetes, dyslipidemia, smoking, obesity, alcohol, poor diet, and inactivity, account for over 90% of stroke risk. Hypertension is the dominant one. A 10 mmHg rise in genetically predicted systolic pressure was linked to a 1.37-fold higher hazard of IS and a 1.71-fold higher hazard of hemorrhagic stroke. Blood pressure control is associated with a 42% lower stroke incidence and a 63% lower hemorrhagic stroke risk. Diabetes accounts for 22.6% of population-attributable stroke risk, and impaired glucose tolerance for 20%. Type 1 diabetes carried a 2.54-fold higher IS risk.

Fewer than 10% of IS patients receive IV thrombolysis, and only about 7–15% receive endovascular therapy, so most patients cannot benefit from reperfusion. The authors argue that stem cell therapy may help by extending penumbra salvage, damping inflammation, and promoting neurogenesis and angiogenesis in animal models. Preclinical results are promising, but clinical benefit still needs confirmation.

Caveats: this is a narrative review that mixes heterogeneous sources, and the provided text cuts off in the diabetes section. The signaling pathway, clinical management, and stem cell sections could not be assessed in detail.

Key Findings

  • Stroke causes 11.9 million new cases and 7.3 million deaths yearly; low- and middle-SDI regions bear 86% of deaths.
  • Modifiable risk factors such as hypertension, diabetes, and smoking account for over 90% of stroke risk.
  • Cumulative stroke risk after TIA reaches 5.0% at 30 days and 7.4% at 90 days.
  • Blood pressure control is associated with 42% lower stroke incidence and 63% lower hemorrhagic stroke risk.
  • Fewer than 10% of ischemic stroke patients get thrombolysis, which motivates regenerative options such as stem cell therapy.

Methodology

This is a narrative review synthesizing published epidemiological studies, meta-analyses, cohort studies, and Global Burden of Disease data on stroke. It has no original data and no stated systematic search protocol or quality appraisal. The supplied full text ends midway through the diabetes subsection.

Study Limitations

As a narrative review, it may be subject to selection bias, and it combines studies with differing definitions and populations. The text provided stops before the signaling pathway, treatment, and stem cell sections, so conclusions about regenerative therapy rest on the introduction only. Stem cell evidence is described mainly as preclinical or early clinical, not definitive.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: